ERBB2 and breast cancer: The primary objective of this FLEX trial analysis was to estimate adjuvant chemotherapy benefit as a function of the continuous MammaPrint Index using 5-year real-world outcome data from a propensity score-matched cohort of patients with HR+HER2- early-stage BC treated with adjuvant endocrine therapy (ET) only or with both ET and chemotherapy (ET+CT).